Sürdürülebilir Kalkınma Amaçları

• 2

Yazarlar

• Can, Ozgur Devrim(1)
• Gundogdu, Betul(1)
• Hacimuftuoglu, Ahmet(1)
• Hjoughi, Ali Taghizadehghale(1)
• Mohammadzadeh, Maryam(1)
• Nalci, Kemal Alp(1)
• Okkay, Ufuk(1)
• Taspinar, Numan(1)
• Togar, Basak(1)
• Ulupinar, Emel(1)
• Yücel, Nazli Turan(1)
• Özkay, Umide Demir(1)
• Üçel, Umut Irfan(1)

• MakaleAçık Erişim2023/r/bayburt/14110
  Effect of Reboxetine Treatment on BDNF, Synaptophysin, and PSD-95 Levels in the Spinal Dorsal Horn of Rats with Diabetic Neuropathy

  Yücel, Nazli Turan; Üçel, Umut Irfan; Özkay, Umide Demir; Ulupinar, Emel; Can, Ozgur Devrim

  Objective: It is known that neuropathic pain is accompanied by alterations in the levels of neurotrophic factors and synaptic proteins in the microenvironment of the spinal dorsal horn. Such changes contribute to hyperalgesia and allodynia processes; thus, analgesic drugs can exert their pharmacological effects by affecting the expressions, levels, or functions of these endogenous substances. In this study, based on the knowledge that reboxetine (a selective noradrenaline reuptake inhibitor) has the potential for antihyperalgesic efficacy in diabetic neuropathy, we aimed to examine the probable effects of this drug on diabetes-induced changes in brain-derived neurotrophic factor (BDNF), synaptophysin (the pre-synaptic marker of synaptic integration), and postsynaptic density-95 (PSD-95) (the postsynaptic marker of synaptic integration) levels in the superficial laminae of the dorsal horn.Methods: Experimental diabetes was induced by a single-dose injection of streptozotocin (STZ) (50 mg/kg) in rats. After four week-long induction period of painful diabetic neuropathy, rats were treated orally with 8 mg/kg reboxetine for two weeks. Hyperalgesia responses were evaluated by using the Randall-Selitto and Hargreave's tests. Following the pain tests, immunohistochemical studies were performed.Results: Two weeks of reboxetine administration increased the reduced paw withdrawal thresholds and shortened the paw withdrawal latencies of diabetic rats in neuropathic pain tests, indicating the antihyperalgesic efficacy of this drug. Moreover, augmented BDNF and synaptophysin levels in diabetic rats reversed by reboxetine treatment. However, there was no alteration in the densities of PSD-95, in both STZ-diabetic and reboxetine-treated STZ-diabetic rats.Conclusion: The obtained results suggested that inhibition of central sensitization and modulation of spinal plasticity seem to be pharmacological mechanisms underlying reboxetine's antihyperalgesic effects on diabetic rats. However, further studies are still needed to clarify the exact mechanism of action.

  • 
  AtıfWoS1·OpenAlex1

  İncele
• MakaleAçık Erişim2020Scopus SJRQ3/r/bayburt/13442
  The analgesic effect of metformin on paclitaxel-induced neuropathic pain model in rats: By considering pathological results

  Hacimuftuoglu, Ahmet; Mohammadzadeh, Maryam; Hjoughi, Ali Taghizadehghale; Taspinar, Numan; Togar, Basak; Nalci, Kemal Alp; Okkay, Ufuk; Gundogdu, Betul

  Background and Objective: Metformin (MET) has been used as an antidiabetic agent for type II diabetes. At the same time, recent researches have shown that the clinical improvement of MET is useful for nerve damage. In this study, we investigated the analgesic effect of MET in paclitaxel (PAC)-induced neuropathic pain. Materials and Methods: Forty-two adult, female rats, Wistar strain weighing 220 ± 10 g were randomly divided into 5 experimental groups. PAC was intraperitoneally (IP) administered (2.0 mg/kg) for 4 groups every other day (0, 2, 4, and 6 days). By the 30th day, MET (100, 200, and 400 mg/kg) was administered to 4 groups. Before and after treatment, basal pain threshold values were measured with Randall-Selitto analgesiometer test. At the end of experiment, pathological values were measured in selected regions including brain (motor cortex, M1), spinal cord (L4-L5), sciatic nerve, and muscle. Results: According to our results, PAC-induced neuropathic pain reached to highest level at 14th day. Four hundred milligram/kilogram concentration of MET remarkably decreased PAC-induced neuropathic pain. On the other hand, pathologic features have shown that PAC had significant pathological change in the brain and spinal cord while in the peripheral nerves and muscles had not shown any pathological change. Conclusion: The pathological results of the current study for the first time demonstrated that MET beside of its antidiabetic effects reversed neuropathic pain induced by PAC. Consequently, this research can be promising for cancer patients that suffering from neuropathic pain induced by anticancer drugs.

  • 
  AtıfScopus12·WoS12·OpenAlex13

  İncele